Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

and a low rate of stent thrombosis from zero to three years, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)*. The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

Event rates based on Kaplan-Meier estimates; p-values are for descriptive purposes only.

"The data from the SPIRIT family of trials continue to prove that XIENCE V is an excellent option for patients. Physicians have embraced this technology, as demonstrated by the market-leading position of XIENCE V around the world," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Our next-generation drug eluting stent in development, XIENCE PRIME, builds upon the outstanding body of clinical evidence from the SPIRIT family of clinical trials, while the new stent design and its delivery system build upon the excellent performance of the VISION cobalt chromium platform, improving deliverability and helping physicians treat difficult lesions."

XIENCE V is the market-leading drug eluting stent platform, with 50 percent share in the United States, and market-leading share around the world.

Abbott's next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System utilizes the same drug and polymer as Abbott's market-leading XIENCE V stent and builds upon the proven design of the MULTI-LINK(R) family of stents. XIENCE PRIME features a new stent design and delivery system that are designed to make it more flexible for improved deliverability. Abbott plans to make XIENCE PRIME available in an expanded size matrix with lengths up to 38 mm. The company expects to launch XIENCE PRIME in Europe later this year.

About the SPIRIT II Trial

SPIRIT II is a prospective
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... mayo de 2013 La junta directiva ... incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, ... junta. Guy Mayer, un ejecutivo ortopédico experimentado, será vicepresidente ... Johnson , un experto refutado en dispositivos ... de unirse a OSI como presidente de la ...
(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... and impressive new product developments at the Special Libraries Association ... years of unerring focus on product literature databases and workflow ... mark the occasion," said founding director Nigel Johnson ... developments of benefit to our clients and what better forum ...
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
Breaking Medicine Technology:Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... robot lawsuit is nearing its conclusion in Washington ... Bloomberg.com, during closing statements yesterday, an attorney for the ... the company wanted to tie sales and services for ... the training to keep control of surgeons, to keep ...
(Date:5/21/2013)... Two executives from human resources and pharmacy ... strategies can be most effective to better manage costly ... who are taking them, in an upcoming May 30 ... Manage Specialty Drugs to Reduce Costs and Ensure Quality ... driver for rising prescription drug costs, which are an ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2
... Paralleling the nation,s efforts to find ways to expand ... care, Concierge Choice Physicians (CCP) announced in ... physicians care for more than 250,000 patients in 12 states - ... Pioneering the concept of hybrid concierge medicine, CCP offers primary care ...
... EAST HAMPTON, N.Y., July 8 The Max Cure Foundation ... cancer causes -- announced today its first charity benefit, the ... day, to take place on Saturday, August 22, from 2:00 ... grounds of the East Hampton Indoor Tennis Club, 175 Daniels ...
... 8 Insulet Corporation (Nasdaq: PODD ), ... that the Company is introducing an environmentally friendly disposal ... Eco-Pod program will reduce the impact of used Pods ... landfills. It is the industry,s first program for ...
... the most famous hotels in Coconut Grove, Florida is now offering ... , In the spirit of game shows of yesterday and today, ... Deal special. It,s simple...call the hotel, mention the Let,s Make a ... suites...the hotel may counter with a Deal or No Deal offer, ...
... July 8 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended June 30, 2009, on Thursday, August 6, ... a conference call and webcast on Thursday, August 6, ... Company,s second quarter results and current corporate developments. The dial-in number ...
... July 8 You,ve just waited through the longest two minutes ... to be positive. After catching your breath, you realize the only ... same again. That,s because you,ve just learned you,re pregnant! This discovery ... mind, and you know you need fast answers. That,s when you ...
Cached Medicine News:Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 2Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System 2Health News:A Unique Rhythm In The Heart Of Coconut Grove, Florida 2Health News:Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:A Bundle of Joy Brings a Bundle of Questions - Life123.com Delivers the Answers! 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: